Health Risks and Breakthroughs: A Mixed Bag
New findings on sleep, chemicals, and medical care raise concerns and offer hope
Read latest briefing →⚕️ Desk
HealthLine
Health, Medicine, Wellness and healthcare developments
Back to Health & Wellness 327 published briefings
Desk archive
Every published briefing in HealthLine.
Feb 11, 2026
Scientists discover how life experiences rewrite the immune system
Recent research reveals how ultra-processed foods, life experiences, and even immune cells can impact our health, while warnings are issued over travel to Cape Verde and cataract blindness.
Feb 7, 2026
Hims & Hers to Stop Selling Compounded Obesity Pill Amid Regulatory Scrutiny and Other Health Controversies
Telehealth company Hims & Hers will cease sales of its compounded version of Novo Nordisk's obesity pill, Wegovy, following a request by the US Department of Health and Human Services (HHS) for the Justice Department to probe the company's practices. This development comes amidst a broader landscape of controversy in healthcare, including debates over gender-affirming care, concerns about the integrity of medical research, and scrutiny of pharmaceutical pricing.
Feb 6, 2026
Trump Administration's Health Initiatives Face Criticism Amidst Layoffs and Withdrawal from WHO
The Trump administration's health initiatives are facing criticism from various quarters, with scientists expressing concerns over the politicization of NIH grant decisions, layoffs at the 'Moonshot' agency ARPA-H, and China accusing the US of sidestepping international law by withdrawing from the WHO.
Feb 6, 2026
Biotech and Pharma News Roundup: TrumpRx Launches, Roivant's Breakthrough, and More
This week in biotech and pharma news, President Trump launched TrumpRx, a website aimed at lowering drug prices, while Roivant's immune drug showed promising results in treating a rare skin disease. Meanwhile, the industry saw a flurry of comings and goings, and companies faced challenges with IPOs and gene therapy.
Feb 6, 2026
Biotech News Roundup: TrumpRx Launches, Roivant's Breakthrough, and More
In a week filled with significant developments in the biotech industry, President Trump launched TrumpRx, a platform aimed at lowering drug prices, while Roivant's immune drug showed promising results in treating a rare skin disease. Meanwhile, the industry saw a flurry of comings and goings, IPOs, and advancements in gene therapy.
Feb 6, 2026
Healthcare in Flux: Evidence, Policy, and the Pursuit of Better Health Outcomes
As the healthcare landscape continues to evolve, concerns about evidence-based policy, effective treatments, and the role of technology in medicine have come to the forefront. From the push for multi-cancer detection tests to the debate over vaccine schedules and the safety of statins, healthcare professionals and policymakers are grappling with complex issues that impact patient care.
Jan 30, 2026
Football's Hidden Danger: Repetitive Head Impacts and the Tragic Death of McQueen
Football and Hyrox share a common thread: physical exertion. However, the risks they pose differ significantly. Hyrox is a fitness craze among young millennials and Generation Z. Football is under scrutiny for its potential hidden dangers. A former footballer's death is linked to chronic traumatic encephalopathy (CTE)
Jan 30, 2026
Polar Bears Thrive Amidst Ice Loss, Sword Health's Big Acquisition, Vets' Price Transparency, and Healthcare News
Polar bears in Svalbard, Norway, have proven to be more resilient than expected. Sword Health, an AI health startup, has agreed to acquire rival Kaia Health for $285 million. The UK government is considering making vets publish prices for common pet treatments.
Jan 5, 2026
Health Policy and Research Updates: A Mixed Bag for Advocates and Scientists
Recent developments in health policy and research have yielded a mix of positive and negative outcomes, with a federal appeals court upholding a ruling blocking NIH's cap on research overhead payments, while federal health officials slash recommended childhood vaccinations, and a cancer drug deal is inked after a biotech IPO.
Jan 5, 2026
Biotech Roundup: New Launches, Leadership Changes, and Advances in Medical Devices
The biotech industry is abuzz with new developments, from the US launch of Novo Nordisk's Wegovy pill to leadership changes at Argenx. Meanwhile, Neuralink is making waves in the field of brain implants, but not everyone is convinced of its intentions. Here's a rundown of the latest news and trends in the biotech sector.
Jan 5, 2026
Global Health in Focus: Innovation, Access, and Advocacy Take Center Stage in 2026
As the world enters a new year, the healthcare landscape is poised for significant developments in biotech innovation, public health data accessibility, and disability advocacy. From China's emerging biotech sector to debates around genetic engineering and end-of-life care, 2026 is shaping up to be a pivotal year for global health.
Jan 5, 2026
Global Health in 2026: Emerging Trends and Challenges in Biopharma, Public Health, and Disability Advocacy
As the world enters a new year, the healthcare landscape is poised to undergo significant changes. From advancements in biopharma to debates around disability advocacy, several key trends are emerging that will shape the future of global health. Experts weigh in on the pressing issues that will dominate the conversation in 2026.
Jan 2, 2026
Healthcare in Flux: Emerging Trends and Challenges in 2026
The healthcare industry is bracing for significant changes in 2026, from the integration of AI technology to shifts in funding priorities. As hospitals navigate the complexities of adopting new medical technology, researchers are making breakthroughs in genetic research and cancer prevention. Meanwhile, the National Institutes of Health is reevaluating its grant priorities, sparking concerns about the future of diversity, equity, and inclusion initiatives.
Jan 2, 2026
Health Care in Flux: Emerging Trends and Challenges in 2026
The health care industry is poised for significant changes in 2026, with emerging trends in AI, genetic research, and funding shifts. As hospitals navigate the complexities of new medical technologies, questions arise about who will pay for these innovations. Meanwhile, researchers uncover new genetic variants that could protect against certain blood cancers, and NIH funding priorities are being reevaluated.